Skip to content
TriangleGet started
A clearer view of the evidence.

THE LATEST IN OUR COLLECTION

Research news.

Sources captured Sep 11, 2026. Not a live or comprehensive feed.

How dates & coverage work

Newest captured updates

Loading search and filters…

  3. FDA notice dated
    FDA announcementFDA

    FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer

    FDA approved camizestrant, an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor for adults with hormone receptor -positive, human epidermal growth factor receptor 2 -negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test.

    Read the captured notice →Original source ↗
  15. FDA notice dated
    FDA announcementFDA

    FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma

    FDA approved vusolimogene oderparepvec-wtpg, a genetically modified oncolytic viral therapy, in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on a programmed death receptor-1 -blocking antibody-based regimen.

    Read the captured notice →Original source ↗
  16. FDA notice dated
    FDA announcementFDA

    FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer

    FDA approved lutetium Lu 177 vipivotide tetraxetan in combination with androgen receptor pathway inhibitor therapy for adults with prostate-specific membrane antigen -positive metastatic androgen pathway modulation-naïve or-sensitive prostate cancer .

    Read the captured notice →Original source ↗
  18. Results first posted
    Trial resultsClinicalTrials.gov

    Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer

    NCT04576091 · Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Recurrent Head and Neck Cutaneous Squamous Cell Carcinoma · Recurrent Head and Neck Squamous Cell Carcinoma · Recurrent Hypopharyngeal Squamous Cell Carcinoma · Recurrent Laryngeal Squamous Cell Carcinoma · Recurrent Oral Cavity Squamous Cell Carcinoma · Recurrent Oropharyngeal Squamous Cell Carcinoma · Recurrent Paranasal Sinus Squamous Cell Carcinoma · Recurrent Salivary Gland Carcinoma · Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8 · Stage III Hypopharyngeal Carcinoma AJCC v8 · Stage III Laryngeal Cancer AJCC v8 · Stage III Lip and Oral Cavity Cancer AJCC v8 · Stage III Major Salivary Gland Cancer AJCC v8 · Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 · Stage III Sinonasal Cancer AJCC v8 · Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8 · Stage IV Hypopharyngeal Carcinoma AJCC v8 · Stage IV Laryngeal Cancer AJCC v8 · Stage IV Lip and Oral Cavity Cancer AJCC v8 · Stage IV Major Salivary Gland Cancer AJCC v8 · Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8 · Stage IV Sinonasal Cancer AJCC v8 · Unresectable Head and Neck Cutaneous Squamous Cell Carcinoma · Unresectable Head and Neck Squamous Cell Carcinoma · Unresectable Hypopharyngeal Squamous Cell Carcinoma · Unresectable Laryngeal Squamous Cell Carcinoma · Unresectable Oral Cavity Squamous Cell Carcinoma · Unresectable Oropharyngeal Squamous Cell Carcinoma · Unresectable Paranasal Sinus Squamous Cell Carcinoma · Unresectable Salivary Gland Squamous Cell Carcinoma · PHASE1

    Found by registry condition search · Source-reported results, not necessarily final

    Explore the results →Original source ↗
  19. Results first posted
    Trial resultsClinicalTrials.gov

    A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

    NCT04640623 · Urinary Bladder Neoplasms · PHASE2

    Cited in NCI / FDA sources · Source-reported results, not necessarily final

    Explore the results →Original source ↗

Search stays in your browser. A newer date does not mean stronger evidence or a better treatment.

About this research feed

Papers are citations captured from NCI source reading, not a comprehensive literature search. Titles and bibliographic metadata are preserved; abstracts and full texts are not included. Corrections, retractions and concerns present in the snapshot are flagged; missing flags do not establish that a paper is unaffected.

Trial entries use the date results were first posted, not the date a registry record was last updated. Dates marked estimated by the source stay explicitly labelled. An administrative update is not presented as new findings. Cited trials and condition-search discoveries are labelled separately; this is not a representative sample of all trials.

Papers use the supplied online-publication date when available, otherwise the supplied publication date. Partial dates stay partial and sort after precisely dated entries in the same month or year. An FDA notice is not confirmation of current approved use or a treatment recommendation. Safety notices are distinct from approvals.

0 records without a usable event date and 0 with dates after the release cutoff are not placed in the dated feed. The original records remain in the source library.

Preserved source evidence · Independent clinical review pending · Not medical advice